LOGIN
Oral salmon calcitonin reduces bone and cartilage degradation markers in patients with OA
March 2013
Oral salmon calcitonin reduces bone and cartilage degradation markers in patients with OA
Study Type:Therapy
OE Level Evidence:2
Journal Level of Evidence:N/A
The effect of oral salmon calcitonin delivered with 5-CNAC on bone and cartilage degradation in osteoarthritic patients: a 14-day randomized study
Osteoarthritis Cartilage. 2010 Feb;18(2):150-9. Epub 2009 Sep 1.Did you know you're eligible to earn 0.5 CME credits for reading this report? Click Here
Synopsis
73 patients, aged 57-75 years of age, with painful OA being experienced in at least one knee, were randomly placed into 3 groups to test the pharmacokinetic and pharmacodynamic effect of oral salmon calcitonin (sCT). Two of the groups received varying dosages of oral sCT (0.6 mg vs. 0.8) while the third group received a placebo. Results demonstrated that patients who received oral sCT had lower bo...
To view the full content, login to your account,
or start your 30-day FREE Trial today.
FREE TRIAL
LOGIN
Forgot Password?
Explore some of our unlocked ACE Reports below!
Learn about our AI Driven
High Impact Search Feature
Our AI driven High Impact metric calculates the impact an article will have by considering both the publishing journal and the content of the article itself. Built using the latest advances in natural language processing, OE High Impact predicts an article’s future number of citations better than impact factor alone.
Continue
Join the Conversation
Please Login or Join to leave comments.